logo
Plus   Neg
Share
Email

Sanofi : EU Okays Libtayo For Advanced Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF,SNY) said that the European Commission granted conditional marketing authorization for Libtayo or cemiplimab to treat adults with metastatic or locally advanced cutaneous squamous cell carcinoma, who are not candidates for curative surgery or curative radiation.

Cutaneous squamous cell carcinoma is one of the most commonly diagnosed skin cancers worldwide, and and is especially difficult to treat in advanced stages.

Libtayo is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. The recommended dose of Libtayo is 350 mg every 3 weeks administered by intravenous infusion over 30 minutes. Treatment may be continued until disease progression or unacceptable toxicity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world. Humanscale Corp. recalled about 24,900 units of QuickStand Lite workstations for concerns of injury hazard. These include about 2,200 units sold in Canada. The recalled workstation's arm can break and cause the workstation to fall, posing a risk of injury. The company has already received 52 reports of the arm breaking, including 12 reports of minor injuries. Facebook has revealed more details on the structure of an independent "oversight board" that will make final decisions about what posts stay up or come down, even if the company disagrees. The new "Oversight Board" will govern appeals from both Facebook and its users.
Follow RTT